Key Points
- Elvia Cowan sold 3,000 shares of Vaxcyte on April 7 at an average price of $60 under a pre-arranged Rule 10b5-1 plan, generating $180,000 and reducing her holdings to 28,975 shares (a 9.38% decrease).
- The April sale continues recent insider dispositions — Cowan also sold 1,892 shares on March 17 and 2,500 shares on March 11 — indicating multiple insider sales in recent weeks.
- Vaxcyte trades around $60 with a market cap of about $8.65B, recently reported an earnings miss (EPS -$1.80 vs. -$1.46 expected), and carries a consensus “Moderate Buy” analyst rating with an average target of $86.
Vaxcyte, Inc. (NASDAQ:PCVX - Get Free Report) CAO Elvia Cowan sold 3,000 shares of the stock in a transaction dated Tuesday, April 7th. The stock was sold at an average price of $60.00, for a total transaction of $180,000.00. Following the sale, the chief accounting officer owned 28,975 shares of the company's stock, valued at $1,738,500. This trade represents a 9.38% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Elvia Cowan also recently made the following trade(s):
- On Tuesday, March 17th, Elvia Cowan sold 1,892 shares of Vaxcyte stock. The stock was sold at an average price of $55.57, for a total transaction of $105,138.44.
- On Wednesday, March 11th, Elvia Cowan sold 2,500 shares of Vaxcyte stock. The stock was sold at an average price of $58.59, for a total transaction of $146,475.00.
Vaxcyte Stock Down 1.0%
Shares of Vaxcyte stock opened at $60.10 on Thursday. The stock has a market capitalization of $8.65 billion, a P/E ratio of -10.69 and a beta of 1.38. The company has a 50-day simple moving average of $56.97 and a 200 day simple moving average of $49.02. Vaxcyte, Inc. has a 12-month low of $27.66 and a 12-month high of $65.00.
Vaxcyte (NASDAQ:PCVX - Get Free Report) last announced its earnings results on Tuesday, February 24th. The company reported ($1.80) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.46) by ($0.34). During the same period last year, the business posted ($1.12) EPS. On average, equities analysts anticipate that Vaxcyte, Inc. will post -4.21 earnings per share for the current year.
Analyst Ratings Changes
PCVX has been the subject of several research reports. Needham & Company LLC raised their price objective on shares of Vaxcyte from $90.00 to $110.00 and gave the company a "buy" rating in a research report on Wednesday, January 7th. BTIG Research upped their price objective on Vaxcyte from $85.00 to $89.00 and gave the stock a "buy" rating in a report on Wednesday, February 25th. Jefferies Financial Group reaffirmed a "buy" rating on shares of Vaxcyte in a report on Tuesday, March 10th. Guggenheim reaffirmed a "buy" rating and set a $116.00 price objective on shares of Vaxcyte in a report on Monday, February 2nd. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Vaxcyte in a report on Friday, January 9th. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $86.00.
View Our Latest Report on PCVX
Institutional Investors Weigh In On Vaxcyte
Several large investors have recently bought and sold shares of PCVX. Royal Bank of Canada increased its stake in Vaxcyte by 115.2% in the first quarter. Royal Bank of Canada now owns 29,471 shares of the company's stock valued at $1,113,000 after purchasing an additional 15,774 shares in the last quarter. Cubist Systematic Strategies LLC acquired a new position in shares of Vaxcyte in the first quarter valued at approximately $219,000. Caxton Associates LLP acquired a new position in shares of Vaxcyte in the first quarter valued at approximately $226,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of Vaxcyte by 8.7% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 513,998 shares of the company's stock valued at $19,409,000 after buying an additional 41,034 shares during the period. Finally, Cetera Investment Advisers boosted its holdings in shares of Vaxcyte by 13.8% in the second quarter. Cetera Investment Advisers now owns 7,681 shares of the company's stock valued at $250,000 after buying an additional 932 shares during the period. Institutional investors own 96.78% of the company's stock.
About Vaxcyte
(
Get Free Report)
Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company's platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.
Vaxcyte's lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
